charges have been excluded from net income or loss because they have
a significant impact on results yet do not occur on a consistent or
regular basis in the Company's business.
(c) Amortization expense of $25.6 million and $5.4 million included in
the fourth quarter of 2007 and 2006 GAAP results, respectively,
including $10.2 million and $2.7 million charged to cost of sales,
$0.7 million and $1.0 million charged to research and development,
$14.6 million and $1.5 million charged to selling, general and
administrative expense, and $0.1 million and $0.2 million charged to
other income, in the respective quarters.
(d) Compensation costs of $5.3 million and $1.6 million associated with
stock-based compensation expense, including $0.3 million and $0.1
million charged to cost of sales, $0.9 million and $.5 million
charged to research and development and $4.1 million and $1.0
million charged to selling, general and administrative.
(e) Loss of $0.3 million associated with management's decision to
dispose of our SMB research facility.
(f) Write-offs in the amount of $0.7 million and $0.1 million during the
three months ended December 31, 2007, relating to inventory
adjustments recorded in connection with the acquisition of
Cholestech and HemoSense, respectively.
(g) Purchase of in-process research and development during the three
months ended December 31, 2007 includes a write-off of $4.8 million
associated with the value of in-process research and development
costs incurred in connection with our acquisition of Diamics.
(h) A $3.9 million unrealized foreign currency loss associated with a
cash escrow established in connection with the acquisition of BBI
|SOURCE Inverness Medical Innovations|
Copyright©2008 PR Newswire.
All rights reserved